Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLADE: Gestrinone Pellet for Pelvic Pain Secondary to Endometriosis
NCT05570786Phase 2Completed
- Sponsor
- Science Valley Research Institute
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometriosis comparing Gestrinone with Placebo (2 arms). Primary endpoint: Serious Adverse Events at 6 months. Started Feb 2023; status: completed.
02
Drugs
Gestrinone
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT05570786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570786.